← Leaderboards
John B Buse
University Of North Carolina Chapel Hill
$71,388,050
Attributed
$123,318,838
Total exposure
33
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $12.7M · FY2007–23$20M$15M$10M$5M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$123,318,838 · 33
By mechanism
UL1$86,705,205 · 2
M01$19,457,262 · 27
UM1$10,042,058 · 1
KL2$4,438,153 · 1
R01$2,356,425 · 1
TL1$319,735 · 1
Top collaborators
- Timothy S Carey19 shared
- Nicholas J Shaheen9 shared
- Michael Jay Wagner4 shared
Most similar at University Of North Carolina Chapel Hill
Same institution · by research overlap
- Nicholas J Shaheen$48,001,410
- Alexander Tropsha$20,747,501
- Timothy S Carey$37,844,352
- Frank C Church$1,886,174
- Joseph Largay$0
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectHuman Therapy EvaluationDiabetes Mellitus TherapyNoninsulin Dependent Diabetes MellitusDrug Screening /EvaluationInsulinClinical TrialsResearch PersonnelInstitutionHypoglycemic AgentsClinical SciencesTranslational ResearchNorth CarolinaInsulin Dependent Diabetes MellitusServicesProgramsCommunitiesInstitutesTrainingResearch TrainingCombination ChemotherapyFundingMetformin
Grant awards (173)
North Carolina Translational and Clinical Sciences Institute (NC TraCS)$10,042,058
UM1 · FY2023 · TR
North Carolina Translational and Clinical Science Institute (NC TraCS)$9,945,630
UL1 · FY2022 · TR · contact PI
North Carolina Translational and Clinical Science Institute (NC TraCS)$218,324
UL1 · FY2022 · TR · contact PI
North Carolina Translational and Clinical Science Institute (NC TraCS)$10,093,886
UL1 · FY2021 · TR · contact PI
CAMP FHIR: Lightweight, Open-Source FHIR Conversion Software to Support EHR Data Harmonization and Research$203,479
UL1 · FY2021 · TR · contact PI
CTSA Diversity Supplement - Vielot - Effectiveness of Recombinant Herpes Zoster Vaccine in Older U.S. Adults$169,963
UL1 · FY2021 · TR · contact PI
North Carolina Translational and Clinical Science Institute (NC TraCS)$9,279,679
UL1 · FY2020 · TR · contact PI
ICEES+ COVID-19 Open Infrastructure to Democratize and Accelerate Cross-Institutional Clinical Data Sharing and Research$412,692
UL1 · FY2020 · TR · contact PI
Re-Entry Supplement: Investigation of Oral Microbial Enzymes for the Detection and Treatment of Periodontal Disease$202,522
UL1 · FY2020 · TR · contact PI
Diversity Supplement: Delivery of Anaerobic Microbes to Treat Ulcerative Colitis$98,307
UL1 · FY2020 · TR · contact PI
CTSA Administrative Supplement for Quality Assurance/Quality Control Position$97,147
UL1 · FY2020 · TR · contact PI
North Carolina Translational and Clinical Science Institute (NC TraCS)$8,982,041
UL1 · FY2019 · TR · contact PI
North Carolina Translational and Clinical Science Institute (NC TraCS)$153,660
UL1 · FY2019 · TR · contact PI
North Carolina Translational and Clinical Science Institute (NC TraCS)$8,757,478
UL1 · FY2018 · TR · contact PI
North Carolina Translational & Clinical Sciences Institute (NC TraCS)$8,920,676
UL1 · FY2017 · TR · contact PI
North Carolina Translational & Clinical Sciences Institute (NC TraCS)$218,202
KL2 · FY2017 · TR · contact PI
North Carolina Translational & Clinical Sciences Institute (NC TraCS)$168,804
UL1 · FY2017 · TR · contact PI
North Carolina Translational & Clinical Sciences Institute (NC TraCS)$1
TL1 · FY2017 · TR · contact PI
North Carolina Translational & Clinical Sciences Institute (NC TraCS)$9,589,835
UL1 · FY2016 · TR · contact PI
North Carolina Translational & Clinical Sciences Institute (NC TraCS)$2,109,975
KL2 · FY2016 · TR · contact PI
North Carolina Translational & Clinical Sciences Institute (NC TraCS)$150,988
TL1 · FY2016 · TR · contact PI
North Carolina Translational & Clinical Sciences Institute (NC TraCS)$9,664,137
UL1 · FY2015 · TR · contact PI
An Exome-Focused Approach to Pharmacogenetic Analysis of the ACCORD Trial$363,729
R01 · FY2015 · HL · contact PI
North Carolina Translational & Clinical Sciences Institute (NC TraCS)$10,836
UL1 · FY2015 · TR · contact PI
North Carolina Translational & Clinical Sciences Institute (NC TraCS)$1
KL2 · FY2015 · TR · contact PI
North Carolina Translational & Clinical Sciences Institute (NC TraCS)$1
TL1 · FY2015 · TR · contact PI
North Carolina Translational & Clinical Sciences Institute (NC TraCS)$9,736,109
UL1 · FY2014 · TR · contact PI
North Carolina Translational & Clinical Sciences Institute (NC TraCS)$2,109,975
KL2 · FY2014 · TR · contact PI
An Exome-Focused Approach to Pharmacogenetic Analysis of the ACCORD Trial$666,552
R01 · FY2014 · HL · contact PI
North Carolina Translational & Clinical Sciences Institute (NC TraCS)$168,745
TL1 · FY2014 · TR · contact PI
An Exome-Focused Approach to Pharmacogenetic Analysis of the ACCORD Trial$609,477
R01 · FY2013 · HL · contact PI
An Exome-Focused Approach to Pharmacogenetic Analysis of the ACCORD Trial$716,667
R01 · FY2012 · HL · contact PI
CLINICAL TRIAL: ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES TRIAL (ACCORD)$459
M01 · FY2008 · RR · contact PI
NMR & CHEMICAL LIPID ANALYSIS IN PATIENTS WITH TYPE 2 DIABETES$6,190
M01 · FY2007 · RR · contact PI
ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES TRIAL (ACCORD)$2,626
M01 · FY2007 · RR · contact PI
PIMAGEDINE IN PATIENT WITH TYPE II DIABETES AND OVERT DIABETIC NEPHROPATHY$190,747
M01 · FY2002 · RR
INSULIN DELIVERY USING NEW LILLY 3 0 ML DISPOSABLE PEN DEVICE$190,747
M01 · FY2002 · RR
ZENARESTAT (CI 1014) IN TREATMENT OF DIABETIC NEUROPATHY$190,747
M01 · FY2002 · RR
ORAL GI262570X IN PATIENTS W/ TYPE 2 DIABETES MELLITUS$190,747
M01 · FY2002 · RR
TRIAL COMPARING HOE 901 &NPH HUMAN INSULIN SUBJECTS W/ TYPE I DIABET$190,747
M01 · FY2002 · RR
24-WEEK DOUBLE-BLIND STUDY OF TROGLITAZONE$190,747
M01 · FY2002 · RR
54 WEEK OPEN LABEL ASSESSMENT OF SAFETY/EFFICACY OF ATORVASTATIN/SIMVASTATIN$190,747
M01 · FY2002 · RR
COMPARISON OF HUMAN INSULIN ANALOGUE X14 IN TYPE I DIABETES$190,747
M01 · FY2002 · RR
AMINOGUANIDINE IN DIABETIC PATIENTS WITH OVERT DIABETIC NEPHROPATHY$190,747
M01 · FY2002 · RR
EFFICACY TRIAL OF VOGLIBOSE (A)-1128 2 MG IN TYPE II DIABETES$190,747
M01 · FY2002 · RR
ATORVASTATIN AS SECONDARY PREVENTION OF CORONARY HEART DISEASE$190,747
M01 · FY2002 · RR
TROGLITAZONE VS PLACEBO IN NONINSULIN DEPENDENT DIABETES MELLITUS$190,747
M01 · FY2002 · RR
CLINICAL TRIAL COMPARING HOE 901 INSULIN WITH NPH HUMAN INSULIN TYPE I$190,747
M01 · FY2002 · RR
CLINICAL TRIAL COMPARING HOE 901 INSULIN WITH NPH HUMAN INSULIN IN NIDDM$190,747
M01 · FY2002 · RR
NIASPAN IN TYPE 2 DIABETIC PATIENTS W/ DYSLIPIDEMIA$190,747
M01 · FY2002 · RR
570X AS MONOTHERAPY FOR SUBJECTS W/ TYPE 2 DIABETES$190,747
M01 · FY2002 · RR
METFORMIN/GLYBURIDE AS 1ST LINE THERAPY IN TYPE 2 DIABETES$190,747
M01 · FY2002 · RR
ATORVASTATIN AS SECONDARY PREVENTION OF CORONARY HEART DISEASE$294,555
M01 · FY2001 · RR
INSULIN DELIVERY USING NEW LILLY 3 0 ML DISPOSABLE PEN DEVICE$294,555
M01 · FY2001 · RR
METFORMIN/GLYBURIDE AS 1ST LINE THERAPY IN TYPE 2 DIABETES$294,555
M01 · FY2001 · RR
570X AS MONOTHERAPY FOR SUBJECTS W/ TYPE 2 DIABETES$294,555
M01 · FY2001 · RR
NIASPAN IN TYPE 2 DIABETIC PATIENTS W/ DYSLIPIDEMIA$294,555
M01 · FY2001 · RR
AMINOGUANIDINE IN DIABETIC PATIENTS WITH OVERT DIABETIC NEPHROPATHY$294,555
M01 · FY2001 · RR
TROGLITAZONE VS PLACEBO IN NONINSULIN DEPENDENT DIABETES MELLITUS$294,555
M01 · FY2001 · RR
PIMAGEDINE IN PATIENT WITH TYPE II DIABETES AND OVERT DIABETIC NEPHROPATHY$294,555
M01 · FY2001 · RR
CLINICAL TRIAL COMPARING HOE 901 INSULIN WITH NPH HUMAN INSULIN TYPE I$294,555
M01 · FY2001 · RR
CLINICAL TRIAL COMPARING HOE 901 INSULIN WITH NPH HUMAN INSULIN IN NIDDM$294,555
M01 · FY2001 · RR
EFFICACY TRIAL OF VOGLIBOSE (A)-1128 2 MG IN TYPE II DIABETES$294,555
M01 · FY2001 · RR
COMPARISON OF HUMAN INSULIN ANALOGUE X14 IN TYPE I DIABETES$294,555
M01 · FY2001 · RR
54 WEEK OPEN LABEL ASSESSMENT OF SAFETY/EFFICACY OF ATORVASTATIN/SIMVASTATIN$294,555
M01 · FY2001 · RR
24-WEEK DOUBLE-BLIND STUDY OF TROGLITAZONE$294,555
M01 · FY2001 · RR
TRIAL COMPARING HOE 901 &NPH HUMAN INSULIN SUBJECTS W/ TYPE I DIABET$294,555
M01 · FY2001 · RR
ORAL GI262570X IN PATIENTS W/ TYPE 2 DIABETES MELLITUS$294,555
M01 · FY2001 · RR
ZENARESTAT (CI 1014) IN TREATMENT OF DIABETIC NEUROPATHY$294,555
M01 · FY2001 · RR
ZENARESTAT (CI 1014) IN TREATMENT OF DIABETIC NEUROPATHY$190,747
M01 · FY2001 · RR
ATORVASTATIN AS SECONDARY PREVENTION OF CORONARY HEART DISEASE$190,747
M01 · FY2001 · RR
INSULIN DELIVERY USING NEW LILLY 3 0 ML DISPOSABLE PEN DEVICE$190,747
M01 · FY2001 · RR
EFFICACY TRIAL OF VOGLIBOSE (A)-1128 2 MG IN TYPE II DIABETES$190,747
M01 · FY2001 · RR
24-WEEK DOUBLE-BLIND STUDY OF TROGLITAZONE$190,747
M01 · FY2001 · RR
NIASPAN IN TYPE 2 DIABETIC PATIENTS W/ DYSLIPIDEMIA$190,747
M01 · FY2001 · RR
570X AS MONOTHERAPY FOR SUBJECTS W/ TYPE 2 DIABETES$190,747
M01 · FY2001 · RR
METFORMIN/GLYBURIDE AS 1ST LINE THERAPY IN TYPE 2 DIABETES$190,747
M01 · FY2001 · RR
AMINOGUANIDINE IN DIABETIC PATIENTS WITH OVERT DIABETIC NEPHROPATHY$190,747
M01 · FY2001 · RR
TRIAL COMPARING HOE 901 &NPH HUMAN INSULIN SUBJECTS W/ TYPE I DIABET$190,747
M01 · FY2001 · RR
TROGLITAZONE VS PLACEBO IN NONINSULIN DEPENDENT DIABETES MELLITUS$190,747
M01 · FY2001 · RR
COMPARISON OF HUMAN INSULIN ANALOGUE X14 IN TYPE I DIABETES$190,747
M01 · FY2001 · RR
54 WEEK OPEN LABEL ASSESSMENT OF SAFETY/EFFICACY OF ATORVASTATIN/SIMVASTATIN$190,747
M01 · FY2001 · RR
PIMAGEDINE IN PATIENT WITH TYPE II DIABETES AND OVERT DIABETIC NEPHROPATHY$190,747
M01 · FY2001 · RR
ORAL GI262570X IN PATIENTS W/ TYPE 2 DIABETES MELLITUS$190,747
M01 · FY2001 · RR
CLINICAL TRIAL COMPARING HOE 901 INSULIN WITH NPH HUMAN INSULIN TYPE I$190,747
M01 · FY2001 · RR
CLINICAL TRIAL COMPARING HOE 901 INSULIN WITH NPH HUMAN INSULIN IN NIDDM$190,747
M01 · FY2001 · RR
ORAL GI262570X IN PATIENTS W/ TYPE 2 DIABETES MELLITUS$294,555
M01 · FY2000 · RR
TRIAL COMPARING HOE 901 &NPH HUMAN INSULIN SUBJECTS W/ TYPE I DIABET$294,555
M01 · FY2000 · RR
TRIAL COMPARING HOE 901 &NPH HUMAN INSULIN SUBJECTS W/ TYPE I DIABET$294,555
M01 · FY2000 · RR
TRIAL COMPARING HOE 901 &NPH HUMAN INSULIN SUBJECTS W/ TYPE I DIABET$294,555
M01 · FY2000 · RR
24-WEEK DOUBLE-BLIND STUDY OF TROGLITAZONE$294,555
M01 · FY2000 · RR
24-WEEK DOUBLE-BLIND STUDY OF TROGLITAZONE$294,555
M01 · FY2000 · RR
24-WEEK DOUBLE-BLIND STUDY OF TROGLITAZONE$294,555
M01 · FY2000 · RR
TROGLITAZONE VS PLACEBO IN NONINSULIN DEPENDENT DIABETES MELLITUS$294,555
M01 · FY2000 · RR
COMPARISON OF HUMAN INSULIN ANALOGUE X14 IN TYPE I DIABETES$294,555
M01 · FY2000 · RR
COMPARISON OF HUMAN INSULIN ANALOGUE X14 IN TYPE I DIABETES$294,555
M01 · FY2000 · RR
COMPARISON OF HUMAN INSULIN ANALOGUE X14 IN TYPE I DIABETES$294,555
M01 · FY2000 · RR
EFFICACY TRIAL OF VOGLIBOSE (A)-1128 2 MG IN TYPE II DIABETES$294,555
M01 · FY2000 · RR
TROGLITAZONE VS PLACEBO IN NONINSULIN DEPENDENT DIABETES MELLITUS$294,555
M01 · FY2000 · RR
EFFICACY TRIAL OF VOGLIBOSE (A)-1128 2 MG IN TYPE II DIABETES$294,555
M01 · FY2000 · RR
EFFICACY TRIAL OF VOGLIBOSE (A)-1128 2 MG IN TYPE II DIABETES$294,555
M01 · FY2000 · RR
CLINICAL TRIAL COMPARING HOE 901 INSULIN WITH NPH HUMAN INSULIN IN NIDDM$294,555
M01 · FY2000 · RR
TROGLITAZONE VS PLACEBO IN NONINSULIN DEPENDENT DIABETES MELLITUS$294,555
M01 · FY2000 · RR
CLINICAL TRIAL COMPARING HOE 901 INSULIN WITH NPH HUMAN INSULIN IN NIDDM$294,555
M01 · FY2000 · RR
CLINICAL TRIAL COMPARING HOE 901 INSULIN WITH NPH HUMAN INSULIN IN NIDDM$294,555
M01 · FY2000 · RR
CLINICAL TRIAL COMPARING HOE 901 INSULIN WITH NPH HUMAN INSULIN TYPE I$294,555
M01 · FY2000 · RR
CLINICAL TRIAL COMPARING HOE 901 INSULIN WITH NPH HUMAN INSULIN TYPE I$294,555
M01 · FY2000 · RR
CLINICAL TRIAL COMPARING HOE 901 INSULIN WITH NPH HUMAN INSULIN TYPE I$294,555
M01 · FY2000 · RR
PIMAGEDINE IN PATIENT WITH TYPE II DIABETES AND OVERT DIABETIC NEPHROPATHY$294,555
M01 · FY2000 · RR
PIMAGEDINE IN PATIENT WITH TYPE II DIABETES AND OVERT DIABETIC NEPHROPATHY$294,555
M01 · FY2000 · RR
PIMAGEDINE IN PATIENT WITH TYPE II DIABETES AND OVERT DIABETIC NEPHROPATHY$294,555
M01 · FY2000 · RR
ORAL GI262570X IN PATIENTS W/ TYPE 2 DIABETES MELLITUS$294,555
M01 · FY2000 · RR
ORAL GI262570X IN PATIENTS W/ TYPE 2 DIABETES MELLITUS$294,555
M01 · FY2000 · RR
ORAL GI262570X IN PATIENTS W/ TYPE 2 DIABETES MELLITUS$241
M01 · FY2000 · RR
TROGLITAZONE VS PLACEBO IN NONINSULIN DEPENDENT DIABETES MELLITUS$241
M01 · FY2000 · RR
PIMAGEDINE IN PATIENT WITH TYPE II DIABETES AND OVERT DIABETIC NEPHROPATHY$241
M01 · FY2000 · RR
CLINICAL TRIAL COMPARING HOE 901 INSULIN WITH NPH HUMAN INSULIN TYPE I$241
M01 · FY2000 · RR
CLINICAL TRIAL COMPARING HOE 901 INSULIN WITH NPH HUMAN INSULIN IN NIDDM$241
M01 · FY2000 · RR
EFFICACY TRIAL OF VOGLIBOSE (A)-1128 2 MG IN TYPE II DIABETES$241
M01 · FY2000 · RR
COMPARISON OF HUMAN INSULIN ANALOGUE X14 IN TYPE I DIABETES$241
M01 · FY2000 · RR
24-WEEK DOUBLE-BLIND STUDY OF TROGLITAZONE$241
M01 · FY2000 · RR
TRIAL COMPARING HOE 901 &NPH HUMAN INSULIN SUBJECTS W/ TYPE I DIABET$241
M01 · FY2000 · RR
EFFECTS OF SUBCUTANEOUS ADMINISTRATED AC2993 IN NIDDM$0
M01 · FY2000 · RR
ROSIGLITAZONE W/ GLYBURIDE &METFORMIN IN NIDDM PTS$0
M01 · FY2000 · RR
ROSIGLITAZONE W/ GLYBURIDE &METFORMIN IN NIDDM PTS$0
M01 · FY2000 · RR
ROSIGLITAZONE W/ GLYBURIDE &METFORMIN IN NIDDM PTS$0
M01 · FY2000 · RR
ROSIGLITAZONE W/ GLYBURIDE &METFORMIN IN NIDDM PTS$0
M01 · FY2000 · RR
EFFEC OF A-100 ON GLYCEMIC CONTROL IN OVERWEIGHT NIDDM$0
M01 · FY2000 · RR
EFFEC OF A-100 ON GLYCEMIC CONTROL IN OVERWEIGHT NIDDM$0
M01 · FY2000 · RR
EFFEC OF A-100 ON GLYCEMIC CONTROL IN OVERWEIGHT NIDDM$0
M01 · FY2000 · RR
EFFEC OF A-100 ON GLYCEMIC CONTROL IN OVERWEIGHT NIDDM$0
M01 · FY2000 · RR
GLUCAGON RECEPTOR ANTAGONIST BAY 27-9955 IN NIDDM$0
M01 · FY2000 · RR
GLUCAGON RECEPTOR ANTAGONIST BAY 27-9955 IN NIDDM$0
M01 · FY2000 · RR
GLUCAGON RECEPTOR ANTAGONIST BAY 27-9955 IN NIDDM$0
M01 · FY2000 · RR
GLUCAGON RECEPTOR ANTAGONIST BAY 27-9955 IN NIDDM$0
M01 · FY2000 · RR
AKESIS PRO HEALTH PAK (DIETARY SUPPLEMENT) IN NIDDM$0
M01 · FY2000 · RR
TROGLITAZONE W/SULFONYLUREA OR PLUS METFORMIN IN NIDDM$0
M01 · FY2000 · RR
TROGLITAZONE W/SULFONYLUREA OR PLUS METFORMIN IN NIDDM$0
M01 · FY2000 · RR
TROGLITAZONE W/SULFONYLUREA OR PLUS METFORMIN IN NIDDM$0
M01 · FY2000 · RR
TROGLITAZONE W/SULFONYLUREA OR PLUS METFORMIN IN NIDDM$0
M01 · FY2000 · RR
GENNID--GENETICS OF NON-INSULIN-DEPENDENT DIABETES$0
M01 · FY2000 · RR
GENNID--GENETICS OF NON-INSULIN-DEPENDENT DIABETES$0
M01 · FY2000 · RR
GENNID--GENETICS OF NON-INSULIN-DEPENDENT DIABETES$0
M01 · FY2000 · RR
GENNID--GENETICS OF NON-INSULIN-DEPENDENT DIABETES$0
M01 · FY2000 · RR
NIASPAN IN TYPE 2 DIABETIC PATIENTS W/ DYSLIPIDEMIA$0
M01 · FY2000 · RR
NIASPAN IN TYPE 2 DIABETIC PATIENTS W/ DYSLIPIDEMIA$0
M01 · FY2000 · RR
NIASPAN IN TYPE 2 DIABETIC PATIENTS W/ DYSLIPIDEMIA$0
M01 · FY2000 · RR
NIASPAN IN TYPE 2 DIABETIC PATIENTS W/ DYSLIPIDEMIA$0
M01 · FY2000 · RR
570X AS MONOTHERAPY FOR SUBJECTS W/ TYPE 2 DIABETES$0
M01 · FY2000 · RR
570X AS MONOTHERAPY FOR SUBJECTS W/ TYPE 2 DIABETES$0
M01 · FY2000 · RR
570X AS MONOTHERAPY FOR SUBJECTS W/ TYPE 2 DIABETES$0
M01 · FY2000 · RR
570X AS MONOTHERAPY FOR SUBJECTS W/ TYPE 2 DIABETES$0
M01 · FY2000 · RR
METFORMIN/GLYBURIDE AS 1ST LINE THERAPY IN TYPE 2 DIABETES$0
M01 · FY2000 · RR
METFORMIN/GLYBURIDE AS 1ST LINE THERAPY IN TYPE 2 DIABETES$0
M01 · FY2000 · RR
METFORMIN/GLYBURIDE AS 1ST LINE THERAPY IN TYPE 2 DIABETES$0
M01 · FY2000 · RR
METFORMIN/GLYBURIDE AS 1ST LINE THERAPY IN TYPE 2 DIABETES$0
M01 · FY2000 · RR
INSULIN DELIVERY USING NEW LILLY 3 0 ML DISPOSABLE PEN DEVICE$0
M01 · FY2000 · RR
INSULIN DELIVERY USING NEW LILLY 3 0 ML DISPOSABLE PEN DEVICE$0
M01 · FY2000 · RR
INSULIN DELIVERY USING NEW LILLY 3 0 ML DISPOSABLE PEN DEVICE$0
M01 · FY2000 · RR
INSULIN DELIVERY USING NEW LILLY 3 0 ML DISPOSABLE PEN DEVICE$0
M01 · FY2000 · RR
ZENARESTAT (CI 1014) IN TREATMENT OF DIABETIC NEUROPATHY$0
M01 · FY2000 · RR
ZENARESTAT (CI 1014) IN TREATMENT OF DIABETIC NEUROPATHY$0
M01 · FY2000 · RR
ZENARESTAT (CI 1014) IN TREATMENT OF DIABETIC NEUROPATHY$0
M01 · FY2000 · RR
ZENARESTAT (CI 1014) IN TREATMENT OF DIABETIC NEUROPATHY$0
M01 · FY2000 · RR
PIMAGEDINE IN DIABETIC PTS W/ OVERT DIABETIC NEPHROPATHY$0
M01 · FY2000 · RR
ATORVASTATIN AS COMPARED TO SIMVASTATIN IN DYSLIPIDEMIA$0
M01 · FY2000 · RR
ATORVASTATIN AS COMPARED TO SIMVASTATIN IN DYSLIPIDEMIA$0
M01 · FY2000 · RR
ATORVASTATIN AS COMPARED TO SIMVASTATIN IN DYSLIPIDEMIA$0
M01 · FY2000 · RR
ATORVASTATIN AS COMPARED TO SIMVASTATIN IN DYSLIPIDEMIA$0
M01 · FY2000 · RR
ATORVASTATIN AS PREVENTION OF CHD IN PTS W/ NIDDM$0
M01 · FY2000 · RR
PIMAGEDINE IN DIABETIC PTS W/ OVERT DIABETIC NEPHROPATHY$0
M01 · FY2000 · RR
PIMAGEDINE IN DIABETIC PTS W/ OVERT DIABETIC NEPHROPATHY$0
M01 · FY2000 · RR
PIMAGEDINE IN DIABETIC PTS W/ OVERT DIABETIC NEPHROPATHY$0
M01 · FY2000 · RR